These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22571487)

  • 1. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
    Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
    Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
    [No Abstract]   [Full Text] [Related]  

  • 2. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia.
    Mansouri L; Cahill N; Gunnarsson R; Smedby KE; Tjönnfjord E; Hjalgrim H; Juliusson G; Geisler C; Rosenquist R
    Leukemia; 2013 Feb; 27(2):512-4. PubMed ID: 23138133
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
    Onaindia A; Gómez S; Piris-Villaespesa M; Martínez-Laperche C; Cereceda L; Montes-Moreno S; Batlle A; de Villambrosia SG; Pollán M; Martín-Acosta P; González-Rincón J; Menarguez J; Alvés J; Rodriguez-Pinilla SM; García JF; Mollejo M; Fraga M; García-Marco JA; Piris MA; Sánchez-Beato M
    Haematologica; 2015 May; 100(5):e200-3. PubMed ID: 25552700
    [No Abstract]   [Full Text] [Related]  

  • 4. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
    Greco M; Capello D; Bruscaggin A; Spina V; Rasi S; Monti S; Ciardullo C; Cresta S; Fangazio M; Gaidano G; Foà R; Rossi D
    Hematol Oncol; 2013 Mar; 31(1):54-5. PubMed ID: 22461140
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia: diagnosis and gene mutations].
    Aoki S
    Rinsho Ketsueki; 2014 Oct; 55(10):1981-8. PubMed ID: 25297763
    [No Abstract]   [Full Text] [Related]  

  • 8. New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
    Filip AA
    Leuk Lymphoma; 2013 Sep; 54(9):1876-81. PubMed ID: 23343182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia with SF3B1 mutation.
    Quesada V; Ramsay AJ; Lopez-Otin C
    N Engl J Med; 2012 Jun; 366(26):2530. PubMed ID: 22738114
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
    Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
    Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
    Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
    Rossi D; Spina V; Bomben R; Rasi S; Dal-Bo M; Bruscaggin A; Rossi FM; Monti S; Degan M; Ciardullo C; Serra R; Zucchetto A; Nomdedeu J; Bulian P; Grossi A; Zaja F; Pozzato G; Laurenti L; Efremov DG; Di-Raimondo F; Marasca R; Forconi F; Del Poeta G; Gaidano G; Gattei V
    Blood; 2013 Jun; 121(24):4902-5. PubMed ID: 23637131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.
    Wu X; Tschumper RC; Jelinek DF
    Leukemia; 2013 Nov; 27(11):2264-7. PubMed ID: 23685408
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
    Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
    Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SF3B1 mutations in chronic lymphocytic leukemia.
    Wan Y; Wu CJ
    Blood; 2013 Jun; 121(23):4627-34. PubMed ID: 23568491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
    Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
    Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
    Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
    Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.